CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 202.9% in November

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,070,000 shares, an increase of 202.9% from the November 15th total of 683,300 shares. Based on an average trading volume of 15,090,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group raised shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research note on Tuesday, September 10th.

CNS Pharmaceuticals Stock Down 1.8 %

CNS Pharmaceuticals stock traded down $0.00 during trading hours on Wednesday, reaching $0.11. 2,298,439 shares of the company’s stock were exchanged, compared to its average volume of 5,588,560. The firm’s 50 day simple moving average is $0.12 and its 200 day simple moving average is $1.18. CNS Pharmaceuticals has a twelve month low of $0.10 and a twelve month high of $100.50. The firm has a market capitalization of $6.16 million, a PE ratio of 0.00 and a beta of 2.55.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.